Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Files An 8-K Entry into a Material Definitive Agreement

Item1.01.

On April10, 2017, Keryx Biopharmaceuticals, Inc. (Keryx) entered
into the First Supplemental Indenture (the First Supplement) to
that certain Indenture (the Indenture), dated as of October15,
2015, between Keryx and The Bank of New York Mellon Trust
Company, N.A., as trustee. Under the terms of the First
Supplement, the $125million of Convertible Senior Notes due 2020
(the Notes) issued under the Indenture may not be converted by
the holders thereof, currently Baupost Group Securities, L.L.C.,
until on or after June8, 2017, except in connection with a
fundamental change as defined in the Indenture. After June8,
2017, the Notes will be convertible entirely into shares of Keryx
common stock or cash depending upon the number of shares of Keryx
common stock authorized at the time of such conversion. On or
after June8, 2017, the holders may, at their option, convert the
Notes until the maturity date thereof. The First Supplement also
changes the observation period for determining the cash
conversion price of the Notes from the five (5)trading days
following the conversion date of the Notes to the five (5)trading
days preceding the conversion date of the Notes.

The foregoing summary of the First Supplement does not purport to
be complete and is qualified in its entirety by reference to the
full text of the First Supplement, a copy of which is attached as
Exhibit 10.1 to this Current Report on Form 8-K and is
incorporated herein by reference.

The following exhibits are furnished herewith:

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Recent Trading Information

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) closed its last trading session at with 1,088,590 shares trading hands.